Latest Australian Market News

EDU Holdings has significantly raised its FY25 financial outlook following strong enrolments and cost efficiencies, while announcing a selective buy-back of 12.5% of its shares from major investors.

Big River Industries Ltd has announced a fully underwritten renounceable entitlement offer to raise approximately $10 million, aimed at funding its acquisition of John’s Building Supplies, a leading Western Australian building materials distributor. The offer opens on December 8 and closes on December 17, 2025.

Haranga Resources has commenced underground diamond drilling at its Lincoln Gold Project in California, aiming to convert a historical resource to JORC compliance and explore new high-grade gold zones.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

Temple & Webster Group delivered a robust FY25 with 21% revenue growth and expanded into New Zealand, reaffirming its ambitious growth and profitability targets for FY26.

Comms Group Limited reported a steady FY25 with revenue growth and a strong start to FY26, driven by the recent TasmaNet acquisition and expanding global contracts. The company is targeting over $75 million in annualised revenue and aims to boost EBITDA to $9-10 million.

Metroglass has reported a 5% revenue decline in its half-year results but achieved a significant reduction in net debt and improved profitability, signaling progress in its turnaround strategy amid challenging market conditions.

OMG Group has secured its maiden purchase order for premium SANDAI matcha in Australia, marking a promising start to a new high-margin revenue channel ahead of FY26.

ECS Botanics has achieved a milestone with direct-to-consumer sales exceeding 60% of total revenue, driven by the launch of innovative sugar-free THC gummies and a strategic distribution partnership.

HeraMED has achieved a significant regulatory milestone with the Therapeutic Goods Administration upgrading its HeraBEAT fetal heart rate monitor to Class IIb, making it the only remote home-use device approved in Australia. This positions the company for a potentially lucrative expansion in the Australian maternity care market.

Cash Converters has completed a $25 million equity raise to fund the acquisition of 29 Australian franchise stores, with EZCORP increasing its voting power to nearly 44%.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.